Janux Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the advancement of its novel immunotherapy platforms during a virtual R&D Day webcast. The company is progressing with its clinical candidate, JANX007, a TRACTr targeting prostate-specific membrane antigen (PSMA), currently under investigation in a Phase 1 clinical trial for adult patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, Janux has introduced its second clinical candidate, JANX008, a TRACTr targeting epidermal growth factor receptor (EGFR), being evaluated in a Phase 1 clinical trial for various solid cancers. The company is also advancing CD3-based TRACTr and CD28-based TRACIr programs, including a PSMA-TRACIr for combination use with JANX007, and a TROP2-TRACTr for TROP2+ solid tumors. Furthermore, Janux is developing its first ARM platform program, CD19-ARM, aimed at treating autoimmune diseases, with first-in-human trials anticipated in the first half of 2026. Results from these initiatives will be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.